Physician profile
Boris Vaisman
NPI 1508801994
$10,876.58
in general payments reported to CMS, 2019-2025
57 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,356 · 2020: $1,424 · 2021: $2,010 · 2022: $1,814 · 2023: $1,513 · 2024: $1,306 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,273.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,611.42 | 2019-2025 | Linzess, Viberzi, Vraylar |
| Janssen Pharmaceuticals, INC | $677.48 | 2019-2022 | |
| Amgen INC. | $648.57 | 2019-2025 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $644.54 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $534.24 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $515.14 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $489.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $429.21 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $423.16 | 2019-2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $418.21 | 2022-2025 | |
| Pfizer INC. | $376.94 | 2019-2025 | |
| Allergan, INC. | $311.40 | 2019-2020 | |
| Abbott Laboratories | $261.94 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $240.65 | 2019-2025 | Rybelsus, Ozempic |
| Ironwood Pharmaceuticals, INC | $228.05 | 2020-2025 | Linzess |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Vaisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.